{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:20:57Z","timestamp":1774974057398,"version":"3.50.1"},"reference-count":45,"publisher":"Japan Neurosurgical Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol. Med. Chir.(Tokyo)"],"published-print":{"date-parts":[[2025,5,15]]},"DOI":"10.2176\/jns-nmc.2024-0246","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T22:16:49Z","timestamp":1742509009000},"page":"217-229","source":"Crossref","is-referenced-by-count":1,"title":["Prospects of BRAF\/MEK Inhibitor Therapy in Papillary Craniopharyngiomas with the BRAF V600E Mutation: A Scoping Review"],"prefix":"10.2176","volume":"65","author":[{"given":"Shingo","family":"FUJIO","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University"},{"name":"Pituitary Disorders Center, Kagoshima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafi","family":"ILMANSYAH","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University"},{"name":"Department of Neurosurgery, Faculty of Medicine, Universitas Diponegoro"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"MAKINO","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University"},{"name":"Pituitary Disorders Center, Kagoshima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tareq A.","family":"JURATLI","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Division of Neuro-Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"SUGATA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University"},{"name":"Pituitary Disorders Center, Kagoshima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriz","family":"BAKHTIAR","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, Universitas Diponegoro"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"HANAYA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"971","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1) Larkin SJ, Ansorge O. Pathology and pathogenesis of craniopharyngiomas. Pituitary. 2013;16 (1):9-17. doi: 10.1007\/s11102-012-0418-4","DOI":"10.1007\/s11102-012-0418-4"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2) M\u00fcller HL, Merchant TE, Warmuth-Metz M, et al. Craniopharyngioma. Nat Rev Dis Primers. 2019;5 (1):75. doi: 10.1038\/s41572-019-0125-9","DOI":"10.1038\/s41572-019-0125-9"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3) Fujio S, Hanada T, Yonenaga M, et al. Surgical aspects in craniopharyngioma treatment. Innov Surg Sci. 2021;6 (1):25-33. doi: 10.1515\/iss-2019-1004","DOI":"10.1515\/iss-2019-1004"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4) Mende KC, Kellner T, Petersenn S, et al. Clinical situation, therapy, and follow-up of adult craniopharyngioma. J Clin Endocrinol Metab. 2020;105 (1):dgz043. doi: 10.1210\/clinem\/dgz043","DOI":"10.1210\/clinem\/dgz043"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5) Fujio S, Juratli TA, Arita K, et al. A clinical rule for preoperative prediction of BRAF mutation status in craniopharyngiomas. Neurosurgery. 2019;85 (2):204-10. doi: 10.1093\/neuros\/nyy569","DOI":"10.1093\/neuros\/nyy569"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6) Sekine S, Shibata T, Kokubu A, et al. Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol. 2002;161 (6):1997-2001. doi: 10.1016\/s0002-9440(10)64477-x","DOI":"10.1016\/S0002-9440(10)64477-X"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7) Brastianos PK, Taylor-Weiner A, Manley PE, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014;46 (2):161-5. doi: 10.1038\/ng.2868","DOI":"10.1038\/ng.2868"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8) Subbiah V, Baik C, Kirkwood JM. Clinical development of BRAF plus MEK inhibitor combinations. Trends Cancer. 2020;6 (9):797-810. doi: 10.1016\/j.trecan.2020.05.009","DOI":"10.1016\/j.trecan.2020.05.009"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9) Arbour G, Ellezam B, Weil AG, et al. Upfront BRAF\/MEK inhibitors for treatment of high-grade glioma: a case report and review of the literature. Neurooncol Adv. 2022;4 (1):vdac174. doi: 10.1093\/noajnl\/vdac174","DOI":"10.1093\/noajnl\/vdac174"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Brastianos PK, Shankar GM, Gill CM, et al. Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. J Natl Cancer Inst. 2016;108 (2):djv310. doi: 10.1093\/jnci\/djv310","DOI":"10.1093\/jnci\/djv310"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11) Aylwin SJB, Bodi I, Beaney R. Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor. Pituitary. 2016;19 (5):544-6. doi: 10.1007\/s11102-015-0663-4","DOI":"10.1007\/s11102-015-0663-4"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12) Rostami E, Witt Nystr\u00f6m P, Libard S, et al. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy. Acta Neurochir (Wien). 2017;159 (11):2217-21. doi: 10.1007\/s00701-017-3311-0","DOI":"10.1007\/s00701-017-3311-0"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13) Roque A, Odia Y. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. CNS Oncol. 2017;6 (2):95-9. doi: 10.2217\/cns-2016-0034","DOI":"10.2217\/cns-2016-0034"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Himes BT, Ruff MW, Van Gompel JJ, et al. Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report. J Neurosurg. 2019;130 (4):1299-303. doi: 10.3171\/2017.11.JNS172373","DOI":"10.3171\/2017.11.JNS172373"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15) Juratli TA, Jones PS, Wang N, et al. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer. 2019;125 (17):2910-4. doi: 10.1002\/cncr.32197","DOI":"10.1002\/cncr.32197"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16) Rao M, Bhattacharjee M, Shepard S, et al. Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report. Oncotarget. 2019;10 (57):6038-42. doi: 10.18632\/oncotarget.27203","DOI":"10.18632\/oncotarget.27203"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Bernstein A, Mrowczynski OD, Greene A, et al. Dual BRAF\/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity. J Neurosurg. 2020;133 (6):1704-9. doi: 10.3171\/2019.8.JNS19643","DOI":"10.3171\/2019.8.JNS19643"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18) Di Stefano AL, Guyon D, Sejean K, et al. Medical debulking with BRAF\/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma. Neurooncol Adv. 2020;2 (1):vdaa141. doi: 10.1093\/noajnl\/vdaa141","DOI":"10.1093\/noajnl\/vdaa141"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19) Khaddour K, Chicoine MR, Huang J, et al. Successful use of BRAF\/MEK inhibitors as a neoadjuvant approach in the definitive treatment of papillary craniopharyngioma. J Natl Compr Canc Netw. 2020;18 (12):1590-5. doi: 10.6004\/jnccn.2020.7624","DOI":"10.6004\/jnccn.2020.7624"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20) Butt SUR, Mejias A, Morelli C, et al. BRAF\/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series. Cancer Chemother Pharmacol. 2021;87 (3):437-41. doi: 10.1007\/s00280-021-04234-0","DOI":"10.1007\/s00280-021-04234-0"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21) Chik CL, van Landeghem FKH, Easaw JC, et al. Aggressive childhood-onset papillary craniopharyngioma managed with vemurafenib, a BRAF inhibitor. J Endocr Soc. 2021;5 (5):bvab043. doi: 10.1210\/jendso\/bvab043","DOI":"10.1210\/jendso\/bvab043"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22) Nussbaum PE, Nussbaum LA, Torok CM, et al. Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift. J Clin Pharm Ther. 2022;47 (6):826-31. doi: 10.1111\/jcpt.13600","DOI":"10.1111\/jcpt.13600"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23) Calvanese F, Jacquesson T, Manet R, et al. Neoadjuvant B-RAF and MEK inhibitor targeted therapy for adult papillary craniopharyngiomas: a new treatment paradigm. Front Endocrinol (Lausanne). 2022;13:882381. doi: 10.3389\/fendo.2022.882381","DOI":"10.3389\/fendo.2022.882381"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24) Fasano M, Della Corte CM, Caterino M, et al. Dramatic therapeutic response to dabrafenib plus trametinib in BRAF V600E mutated papillary craniopharyngiomas: a case report and literature review. Front Med (Lausanne). 2022;8:652005. doi: 10.3389\/fmed.2021.652005","DOI":"10.3389\/fmed.2021.652005"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25) Lin AL, Tabar V, Young RJ, et al. Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma. Pituitary. 2023;26 (4):482-7. doi: 10.1007\/s11102-023-01339-y","DOI":"10.1007\/s11102-023-01339-y"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26) Wu ZP, Wang YL, Wang LC, et al. Case report: successful use of BRAF\/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma. World Neurosurg. 2023;180:e117-26. doi: 10.1016\/j.wneu.2023.08.137","DOI":"10.1016\/j.wneu.2023.08.137"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27) Shah SN, Kaki PC, Shah SS, et al. Concurrent radiation and targeted therapy for papillary craniopharyngioma: a case report. Cureus. 2023;15 (6):e40190. doi: 10.7759\/cureus.40190","DOI":"10.7759\/cureus.40190"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Losa M, Mazza E, Pedone E, et al. Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature. J Endocrinol Invest. 2024;47 (11):2835-42. doi: 10.1007\/s40618-024-02382-7","DOI":"10.1007\/s40618-024-02382-7"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29) Yu N, Raslan OA, Lee HS, et al. Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review. CNS Oncol. 2024;13 (1):CNS106. doi: 10.2217\/cns-2023-0018","DOI":"10.2217\/cns-2023-0018"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30) Brastianos PK, Twohy E, Geyer S, et al. BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas. N Engl J Med. 2023;389 (2):118-26. doi: 10.1056\/NEJMoa2213329","DOI":"10.1056\/NEJMoa2213329"},{"key":"31","unstructured":"31) Moola S, Munn Z, Tufanaru C, et al. JBI Manual for Evidence Synthesis. in Aromataris JBI, Lockwood E, Porritt Cet al (eds): North Adelaide, Australia: Joanna Briggs Institute; 2024. Systematic reviews of etiology and risk."},{"key":"32","doi-asserted-by":"publisher","unstructured":"32) Xu C, Ge S, Cheng J, et al. Pathological and prognostic characterization of craniopharyngioma based on the expression of TrkA, \u03b2-catenin, cell cycle markers, and BRAF V600E mutation. Front Endocrinol (Lausanne). 2022;13:859381. doi: 10.3389\/fendo.2022.859381","DOI":"10.3389\/fendo.2022.859381"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33) Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5 (11):875-85. doi: 10.1038\/nrm1498","DOI":"10.1038\/nrm1498"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417 (6892):949-54. doi: 10.1038\/nature00766","DOI":"10.1038\/nature00766"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35) Dankner M, Rose AAN, Rajkumar S, et al. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37 (24):3183-99. doi: 10.1038\/s41388-018-0171-x","DOI":"10.1038\/s41388-018-0171-x"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36) Rizos H, Menzies AM, Pupo GM, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res. 2014;20 (7):1965-77. doi: 10.1158\/1078-0432.CCR-13-3122","DOI":"10.1158\/1078-0432.CCR-13-3122"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37) Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014;4 (1):94-109. doi: 10.1158\/2159-8290.CD-13-0617","DOI":"10.1158\/2159-8290.CD-13-0617"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38) Adelmann CH, Ching G, Du L, et al. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget. 2016;7 (21):30453-60. doi: 10.18632\/oncotarget.8351","DOI":"10.18632\/oncotarget.8351"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Lee CC, Yang HC, Chen CJ, et al. Gamma Knife surgery for craniopharyngioma: report on a 20-year experience. J Neurosurg. 2014;121 (suppl):167-78. doi: 10.3171\/2014.8.GKS141411","DOI":"10.3171\/2014.8.GKS141411"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40) Rutenberg MS, Holtzman AL, Indelicato DJ, et al. Disease control after radiotherapy for adult craniopharyngioma: clinical outcomes from a large single-institution series. J Neurooncol. 2022;157 (3):425-33. doi: 10.1007\/s11060-022-03983-z","DOI":"10.1007\/s11060-022-03983-z"},{"key":"41","doi-asserted-by":"publisher","unstructured":"41) Lamiman K, Wong KK, Tamrazi B, et al. A quantitative analysis of craniopharyngioma cyst expansion during and after radiation therapy and surgical implications. Neurosurg Focus. 2016;41 (6):E15. doi: 10.3171\/2016.9.FOCUS16298","DOI":"10.3171\/2016.9.FOCUS16298"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42) La Corte E, Younus I, Pivari F, et al. BRAF V600E mutant papillary craniopharyngiomas: a single-institutional case series. Pituitary. 2018;21 (6):571-83. doi: 10.1007\/s11102-018-0909-z","DOI":"10.1007\/s11102-018-0909-z"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Taguchi A, Kinoshita Y, Kojima M, et al. Optic tract edema in craniopharyngioma as a predictor of BRAFV600E mutation presence. Jpn J Clin Oncol. 2023;53 (5):378-85. doi: 10.1093\/jjco\/hyad003","DOI":"10.1093\/jjco\/hyad003"},{"key":"44","doi-asserted-by":"publisher","unstructured":"44) Chen X, Tong Y, Shi Z, et al. Noninvasive molecular diagnosis of craniopharyngioma with MRI-based radiomics approach. BMC Neurol. 2019;19 (1):6. doi: 10.1186\/s12883-018-1216-z","DOI":"10.1186\/s12883-018-1216-z"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45) Steiert C, Grauvogel J, Roelz R, et al. Stereotactic cysto-ventricular catheters in craniopharyngiomas: an effective minimally invasive method to improve visual impairment and achieve long-term cyst volume reduction. Neurosurg Rev. 2021;44 (6):3411-20. doi: 10.1007\/s10143-021-01510-8","DOI":"10.1007\/s10143-021-01510-8"}],"container-title":["Neurologia medico-chirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/65\/5\/65_2024-0246\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T03:43:03Z","timestamp":1747453383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/65\/5\/65_2024-0246\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2176\/jns-nmc.2024-0246","relation":{},"ISSN":["0470-8105","1349-8029"],"issn-type":[{"value":"0470-8105","type":"print"},{"value":"1349-8029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"article-number":"2024-0246"}}